ArticleBrain and behavior2025
Immune Evasion Mechanism Mediated by ITPRIPL1 and Its Prognostic Implications in Glioma.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic reprogramming and immunosenescence: a new sight for glioma therapy.Frontiers in cell and developmental biology · 2026Review
- Immune Evasion Mechanism Mediated by ITPRIPL1 and Its Prognostic Implications in Glioma.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGlioma represent one of the most prevalent and lethal malignancies within the central nervous system. Recent studies have identified ITPRIPL1, a newly reported CD3ε-inhibitory ligand, as a suppressor of T cell activation, thereby facilitating tumor immune evasion and offering a novel avenue for immunotherapeutic intervention in glioma.
methodsA comprehensive analysis was performed using datasets from The Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA), and Gene Expression Omnibus (GEO). This included evaluating ITPRIPL1 expression levels in glioma, its association with clinicopathological features, prognostic significance, immune landscape, targeted drug sensitivity, and underlying biological functions. Ninety-eight machine learning algorithm combinations were screened to identify the optimal predictive model. A nomogram was subsequently constructed and validated to assess the integrated prognostic impact of ITPRIPL1 expression on glioma patients.
resultsElevated ITPRIPL1 expression was positively correlated with higher tumor grade and poorer clinical outcomes. Immune infiltration profiling revealed that ITPRIPL1 expression was negatively associated with effector memory CD4⁺ T cells and type 17 T helper cells (Th17), but positively correlated with M2-polarized macrophages and several immune checkpoint molecules. Moreover, drug sensitivity analyses and molecular docking studies highlighted a potential therapeutic relationship between ITPRIPL1 and antitumor agents such as AZD8055. The SuperPC model emerged as the most robust predictor and was utilized to develop a prognostic nomogram capable of reliably forecasting survival in glioma patients.
conclusionsThis study reveals that ITPRIPL1 plays a dual role in glioma: It suppresses T cell-mediated immune responses, contributing to an immunosuppressive microenvironment, and interferes with the efficacy of antitumor drugs, thereby promoting tumor progression and ultimately leading to poor patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.